Announced Wed, 12 Aug · 17:45 IST
Board approves Q1 FY27 results, appoints Statutory and Secretarial Auditors for 5 years
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+3.3%1-day move
₹27.11
prior close
₹27.13
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.2-1.2-1.0-0.8+3.3+2.4+3.2-0.4-0.9+12.3+13.5+23.0——
Up moveDown movePending
AI summary
Mangalam Drugs and Organics board on Aug 12, 2026 approved Q1 FY27 results for quarter ended June 30, 2026. Standalone revenue was Rs 5,711.93 lakhs versus Rs 5,720.87 lakhs year ago. Net loss narrowed sharply to Rs 755.36 lakhs from Rs 1,372.80 lakhs. EPS stood at Rs (4.77) versus Rs (8.67). Board also appointed M/s S.N. Nanda and Co. as Statutory Auditors and M/s L.N. Joshi and Co. as Secretarial Auditors, both for 5 years (53rd to 58th AGM), subject to shareholder approval.
Likely market impact
Auditor appointments are routine; narrowing of loss versus year-ago quarter is mildly positive for sentiment.